Skip to main content
. Author manuscript; available in PMC: 2014 Nov 15.
Published in final edited form as: Clin Cancer Res. 2013 Aug 27;19(22):10.1158/1078-0432.CCR-13-1320. doi: 10.1158/1078-0432.CCR-13-1320

Figure 4.

Figure 4

Biological correlatives for overall survival after treatment with CP-870,893 in combination with gemcitabine. (A) Median overall survival and progression free survival for patients (n=21) receiving at least one dose of CP-870,893. Relationship between (B) percent change in CA19-9 at end of one cycle of therapy compared to baseline (R = −0.579; p = 0.049), (C) overall survival and tumor response determined by RECIST 1.0 at completion of two cycles of therapy (R = −0.652; p = 0.002), and (D) percent change in total MVPmean for all lesions, primary pancreatic lesion, and all hepatic lesions after two weeks of therapy compared to baseline (R = −0.929; p = 0.007). Best overall tumor response measured by RECIST 1.0 is indicated in (B), (C), and (D) using open circles (partial response), grey circles (stable disease), and black circles (progressive disease).